Biscayne's lead GHRH antagonist is in preclinical development initially for the treatment of castrate-resistant prostate cancer (CRPC), a particularly lethal form of prostate cancer affecting 30,000 new patients each year in the US. The GHRH antagonists work through a novel pathway that reduces the levels of hormones fueling the growth of tumors. In animal studies, these antagonists have shown promising anti-tumor activity and were synergistic with chemotherapy. The company believes that GHRH antagonists may have therapeutic potential in many other types of tumors, including breast, brain, lung, colon and skin.
Biscayne's lead GHRH agonists have demonstrated a unique capacity to repair the heart following ischemic injury, such as a heart attack, and are in preclinical development for the repair of damaged cardiac tissue. GHRH agonists directly activate GHRH receptors in the heart, stimulating tissue healing through a variety of mechanisms. GHRH agonists may represent a new class of therapy for cardiac conditions that presently afflict millions of patients worldwide.
In preclinical studies, GHRH agonists improved both cardiac structure and function and reduced myocardial infarct size and scarring, thereby reducing the chance of future heart failure. Joshua M. Hare , MD, a scientific co-founder of Biscayne, who is the Louis Lemberg Professor of Medicine in the University of Miami Health System, is working with Dr. Schally to develop the GHRH technology for coronary heart disease.Dr. Hare noted, "Despite the many advances in cardiovascular therapy, millions of patients are disabled and ultimately killed each year from cardiac damage due to coronary heart disease. Our GHRH agonists represent a unique and powerful approach aimed at developing drugs to reduce and repair this damage. I look forward to working with the Biscayne
|SOURCE Biscayne Pharmaceuticals|
Copyright©2012 PR Newswire.
All rights reserved